(Q44442912)

English

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

scientific article published on 8 October 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

phase II clinical trial

0 references

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

Georgina V. Long

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Caroline Robert

9

object named as

Caroline Robert

0 references

Richard F. Kefford

object named as

Richard F Kefford

4

0 references

Dirk Schadendorf

22

object named as

Dirk Schadendorf

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Paolo Antonio Ascierto

5

object named as

Paolo A Ascierto

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

8

object named as

Axel Hauschild

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

14

object named as

Lisa Zimmer

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

10

object named as

Alain Algazi

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

19

object named as

Vicki Goodman

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Laurent Mortier

11

object named as

Laurent Mortier

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Uwe Trefzer

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Michael A Davies

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Paul B Chapman

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Igor Puzanov

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Hussein Tawbi

12

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Tabea Wilhelm

13

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Julie Switzky

15

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Suzanne Swann

16

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Anne-Marie Martin

17

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Mary Guckert

18

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Michael Streit

20

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

John M Kirkwood

21

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

8 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1087-1095

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

NRAS mutation status is an independent prognostic factor in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for survival in melanoma patients with brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of outcome in melanoma patients with cerebral metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of melanoma brain metastases: a new paradigm.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Inclusion of patients with brain metastases in phase I trials: an unmet need.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel method for volumetric MRI response assessment of enhancing brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The biology of brain metastases-translation to new therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970431-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70431-X

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44442912&oldid=2023677712"